Quartz·1 min read·medium
Vertex Pharmaceuticals is buying Crinetics to expand into rare hormonal diseases
✦AI Summary
Vertex Pharmaceuticals has announced the acquisition of Crinetics to expand its portfolio in the rare hormonal disease market. The deal provides Vertex with access to late-stage treatments for acromegaly and congenital adrenal hyperplasia.
The deal gives Vertex access to Palsonify, an oral acromegaly treatment, and atumelnant, a late-stage drug for congenital adrenal hyperplasia
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in